KERLONE
LOE ApproachingNDAORALTABLET
Approved
Oct 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KERLONE is an oral small-molecule tablet approved in 1989 by Sanofi. The generic name and mechanism of action are not publicly detailed in available records. Patient indication and therapeutic class require additional clinical reference material.
LOE Approaching
Product is approaching loss of exclusivity; commercial teams should expect headcount optimization and transition planning toward generic erosion management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KERLONE currently shows zero linked job openings, reflecting its mature, LOE-approaching status. Careers on this product focus on defensive commercial strategy, generic transition planning, and payer/managed care negotiations rather than growth or launch activities.
Brand ManagerSenior Brand Manager
Worked on KERLONE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.